Table 2 Comparison of the clinical characteristics and management of NSCLC patients according to the type of ILD
Characteristic | Total (n = 141) | IPF-LC (n = 81) | Non-IPF-LC (n = 60) | p Value |
|---|---|---|---|---|
Clinical stage of NSCLC | Â | Â | Â | 0.337 |
 I | 46 (32.9) | 31 (38.3) | 15 (25.0) |  |
 II | 20 (14.3) | 9 (11.1) | 11 (18.3) |  |
 III | 38 (27.1) | 21 (25.9) | 17 (28.3) |  |
 IV | 36 (25.7) | 10 (24.7) | 17 (28.3) |  |
KL-6 (U/mL), n = 98 | 983.7 ± 1111.4 | 907.9 ± 900.1 | 1098.4 ± 1376.12 | 0.409 |
Initial treatment for NSCLC | Â | Â | Â | Â |
 Surgery | 46 (32.6) | 30 (37.0) | 16 (26.7) | 0.194 |
  Lobar resection | 29 (63.0) | 14 (46.7) | 15 (93.8) |  |
  Sublobar resection | 17 (37.0) | 16 (53.3) | 1 (6.3) |  |
 Chemotherapy | 32 (22.7) | 15 (18.5) | 17 (28.3) | 0.169 |
 Radiotherapy | 31 (22.0) | 19 (23.5) | 12 (20.0) | 0.624 |
 CCRT | 7 (5.0) | 1 (1.2) | 6 (10.0) | 0.042 |
 Best supportive care | 25 (17.7) | 16 (19.8) | 9 (15.0) | 0.465 |
Treatment of ILD | Â | Â | Â | Â |
 Antifibrotic agent | 70 (49.6) | 65 (80.2) | 5 (8.3) | < 0.001 |
 Corticosteroid ± IS | 54 (38.3) | 29 (35.8)a | 25 (41.7)b | 0.479 |
  Initial treatment | 17 (12.1) | 5 (6.2) | 12 (20.0) | 0.013 |
  Acute exacerbation | 37 (26.2) | 25 (30.9) | 12 (20.0) | 0.147 |
  RT pneumonitis | 5 (3.5) | 2 (2.5) | 3 (5.0) | 0.651 |
Acute exacerbation | 37 (26.2) | 25 (30.9) | 12 (20.0) | 0.147 |
Overall mortality | 57 (40.4) | 34 (42.0) | 23 (38.3) | 0.663 |
 AE-related death | 21 (36.8) | 14 (41.2) | 7 (30.4) | 0.409 |
 Infection-related death | 15 (26.3) | 7 (20.6) | 8 (34.8) | 0.232 |
 Unknown | 21 (36.8) | 14 (41.2) | 7 (30.4) | 0.409 |